| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent developments have highlighted significant challenges in Insmed's product and service development, marked by the discontinuation of programs and disappointing clinical trial results. The failure of key studies has raised questions about the efficacy of current treatments and has led to doubts regarding the long-term viability of their drug pipeline. However, the company is making efforts to expand its offerings despite setbacks, aiming to introduce new assets that could drive future growth. This duality of struggles and potential reflects the complex landscape in which Insmed operates. |
| The price action of Insmed (INSM) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -1.9 is very bearish. The market sentiment at -0.5 is modestly bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.INSM is likely to move down since both trend sentiment and market sentiment are negative. The positive sentiment force for sector is at 0.6, and the negative at -1.1 on 2025-12-18. The forces of Sentiment towards Fundamentals (-3.3), Stock Price Trend (-1.9), Valuation Sentiment (-1), and Market Risk Appetite (-0.2) will drive down the price. The forces of Sector Price Trend (0.8), Price Level Sentiment (1.5), and Option Sentiment (1.5) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| INSM | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-18 | 1%(0.1%) | 166.55 | -38 | -16.08% | -1.97% | -1.9 | -0.95% | 10.2% | -0.5 | Short | 75% | -3.3 | -7.8 |
| 2025-12-17 | 0%(0%) | 198.46 | 36 | -1.1% | -0.4% | 0.9 | -0.05% | 1.1% | 0.2 | Long | 65% | -0.2 | -1 |
| 2025-12-16 | 0%(0%) | 200.67 | 45 | 1.94% | -0.3% | 0.9 | 0.15% | 1.3% | -0 | Long | 65% | -0.2 | -1 |
| 2025-12-15 | 0%(0%) | 196.85 | 29 | -0.09% | -0.75% | -0.3 | 0.1% | 1% | -0.3 | Long | 65% | -0.8 | -1 |
| 2025-12-14 | 0%(0%) | -0.2 | 0% | -0.8 | -1.2 | -1 | |||||||
| 2025-12-13 | 0%(0%) | -0.2 | 0% | -0.8 | -1.2 | -1 | |||||||
| 2025-12-12 | 0%(0%) | 197.02 | 31 | 0.93% | -0.5% | -0.2 | 0% | 0.7% | -1.1 | Wait | 50% | -2.4 | -1 |
| 2025-12-11 | 0%(0%) | 195.2 | 26 | 2.82% | -0.49% | -0.7 | -0.05% | 0.6% | -1.3 | Wait | 50% | -2.5 | -1 |
| 2025-12-10 | 0%(0%) | 189.85 | 5 | -2.26% | -0.93% | -1.1 | -0.2% | 1% | -1.2 | Short | 65% | -2.2 | -1 |
| 2025-12-09 | 0%(0%) | 194.23 | 20 | -1.18% | -0.63% | -0.6 | -0.25% | 2.2% | -0.9 | Short | 65% | -2.1 | -1 |
| Short is the preferred trading strategy with 75% chance of being right. The trend sentiment, hourly trend, and market sentiment (moving force) are all very bearish. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-12-18 17:10:58 The articles reflect a drop in investor sentiment regarding Insmed's stability and earnings potential after recent failures, raising questions about its financial future. |
| 2025-12-18 17:10:58 Despite the setback from the failed sinus drug, Insmed is attempting to add a new monoclonal antibody asset to its pipeline, suggesting a focus on future growth. |
| 2025-12-18 17:10:58 Insmed's stock reacted negatively in the market after news of the discontinued drug development was released, showing how sensitive stock performance can be to company announcements. |
| 2025-12-18 17:10:58 The articles report on the failure of Insmed's clinical trial for a sinus drug, which has direct implications for its product pipeline and investor confidence. |
| 2025-12-18 17:10:58 Multiple articles highlight the significant decline in Insmed's stock price following the discontinuation of its drug development, reflecting investor concerns about the company's future prospects. |
| 2025-12-18 15:48:13 The decision to discontinue the drug development points to challenges in product/service lifecycle and market viability, suggesting a struggle in advancing their treatment offerings. |
| 2025-12-18 15:48:13 The significant drop in Insmed's stock price following the announcement of discontinuing a drug development indicates a negative sentiment towards the company's current financial health. |
| 2025-12-18 13:48:49 The discontinuation of the brensocatib program following missed trial endpoints indicates significant setbacks in product development. |
| 2025-12-18 13:48:49 Despite the poor performance of brensocatib, analysts maintain a bullish outlook on Insmed's other assets. |
| 2025-12-18 13:48:49 Insmed's stock is falling due to the failure of brensocatib in clinical trials, negatively impacting investor sentiment. |
| 2025-12-18 11:49:09 The decision to discontinue the development of a drug for a chronic sinus condition indicates setbacks in product pipeline and can impact the company's long-term viability. |
| 2025-12-18 11:49:09 The significant drop in Insmed's stock price following the announcement of the discontinuation of a drug development reflects negative investor sentiment and concerns about the company's future prospects. |
| 2025-12-18 09:35:04 Insmed's decision to stop developing a drug aimed at treating a chronic sinus condition contributed to the stock drop. |
| 2025-12-18 09:35:04 The significant drop in Insmed's stock value following the announcement of the discontinuation of a drug development. |